ATRA — Atara Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $94.70m
- $127.81m
- $120.77m
Atara Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Atara Biotherapeutics Q2 EPS USD -3.1
Atara Biotherapeutics Inc expected to post a loss of $1.56 a share - Earnings Preview
Brief: Atara Bio Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel
Brief: Atara Biotherapeutics Announces 1-For-25 Reverse Stock Split
Brief: Atara Biotherapeutics Presents Preclinical Data On Ata3219, A Therapy For The Treatment Of B-Cell Driven Autoimmune Diseases
Brief: Adiumentum Capital Fund I LP Says It Acquired Beneficial Ownership Of Atara Biotherapeutics Common Stock Shares In Belief Stock Was Undervalued
Brief: Atara Biotherapeutics Submits Tabelecleucel (Tab-Cel®) Biologics License Application
Atara Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Atara Biotherapeutics Q1 EPS USD -0.23
Atara Biotherapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Atara Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Atara Biotherapeutics Q4 EPS USD -0.56
Brief: Citadel Advisors Reports 6.4% Passive Stake In Atara Biotherapeutics As Of March 8 - SEC Filing
Brief: Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219
Atara Biotherapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Atara Biotherapeutics And Pierre Fabre Laboratories Announce Publication Of Phase 3 Allele Tab-Cel® Data In The Lancet Oncology
Brief: Atara Biotherapeutics To Close Global Tab-Cel® Partnership With Pierre Fabre Laboratories
Brief: Atara Biotherapeutics Presents Positive Preclinical Data On ATA3431